Menu
Home Explore People Places Arts History Plants & Animals Science Life & Culture Technology
On this page
ATC code L01
Therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System: Antineoplastic agents

ATC code L01 Antineoplastic agents is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products. Subgroup L01 is part of the anatomical group L Antineoplastic and immunomodulating agents.

Codes for veterinary use (ATCvet codes) can be created by placing the letter Q in front of the human ATC code: for example, QL01. ATCvet codes without corresponding human ATC codes are cited with the leading Q in the following list.National issues of the ATC classification may include additional codes not present in this list, which follows the WHO version.

We don't have any images related to ATC code L01 yet.
We don't have any YouTube videos related to ATC code L01 yet.
We don't have any PDF documents related to ATC code L01 yet.
We don't have any Books related to ATC code L01 yet.
We don't have any archived web articles related to ATC code L01 yet.

L01A Alkylating agents

L01AA Nitrogen mustard analogues

L01AA01 Cyclophosphamide L01AA02 Chlorambucil L01AA03 Melphalan L01AA05 Chlormethine L01AA06 Ifosfamide L01AA07 Trofosfamide L01AA08 Prednimustine L01AA09 Bendamustine L01AA10 Melphalan flufenamide

L01AB Alkyl sulfonates

L01AB01 Busulfan L01AB02 Treosulfan L01AB03 Mannosulfan

L01AC Ethylene imines

L01AC01 Thiotepa L01AC02 Triaziquone L01AC03 Carboquone

L01AD Nitrosoureas

L01AD01 Carmustine L01AD02 Lomustine L01AD03 Semustine L01AD04 Streptozocin L01AD05 Fotemustine L01AD06 Nimustine L01AD07 Ranimustine L01AD08 Uramustine

L01AG Epoxides

L01AG01 Etoglucid

L01AX Other alkylating agents

L01AX01 Mitobronitol L01AX02 Pipobroman L01AX03 Temozolomide L01AX04 Dacarbazine

L01B Antimetabolites

L01BA Folic acid analogues

L01BA01 Methotrexate L01BA03 Raltitrexed L01BA04 Pemetrexed L01BA05 Pralatrexate

L01BB Purine analogues

L01BB02 Mercaptopurine L01BB03 Tioguanine L01BB04 Cladribine L01BB05 Fludarabine L01BB06 Clofarabine L01BB07 Nelarabine QL01BB90 Rabacfosadine

L01BC Pyrimidine analogues

L01BC01 Cytarabine L01BC02 Fluorouracil L01BC03 Tegafur L01BC04 Carmofur L01BC05 Gemcitabine L01BC06 Capecitabine L01BC07 Azacitidine L01BC08 Decitabine L01BC09 Floxuridine L01BC52 Fluorouracil, combinations L01BC53 Tegafur, combinations L01BC58 Decitabine, combinations L01BC59 Trifluridine, combinations

L01C Plant alkaloids and other natural products

L01CA Vinca alkaloids and analogues

L01CA01 Vinblastine L01CA02 Vincristine L01CA03 Vindesine L01CA04 Vinorelbine L01CA05 Vinflunine L01CA06 Vintafolide

L01CB Podophyllotoxin derivatives

L01CB01 Etoposide L01CB02 Teniposide

L01CC Colchicine derivatives

L01CC01 Demecolcine

L01CD Taxanes

L01CD01 Paclitaxel L01CD02 Docetaxel L01CD03 Paclitaxel poliglumex L01CD04 Cabazitaxel L01CD51 Paclitaxel and encequidar

L01CE Topoisomerase 1 (TOP1) inhibitors

L01CE01 Topotecan L01CE02 Irinotecan L01CE03 Etirinotecan pegol L01CE04 Belotecan

L01CX Other plant alkaloids and natural products

L01CX01 Trabectedin

L01DA Actinomycines

L01DA01 Dactinomycin

L01DB Anthracyclines and related substances

L01DB01 Doxorubicin L01DB02 Daunorubicin L01DB03 Epirubicin L01DB04 Aclarubicin L01DB05 Zorubicin L01DB06 Idarubicin L01DB07 Mitoxantrone L01DB08 Pirarubicin L01DB09 Valrubicin L01DB10 Amrubicin L01DB11 Pixantrone

L01DC Other cytotoxic antibiotics

L01DC01 Bleomycin L01DC02 Plicamycin L01DC03 Mitomycin L01DC04 Ixabepilone L01DC05 Utidelone

L01E Protein kinase inhibitors

L01EA BCR-ABL tyrosine kinase inhibitors

L01EA01 Imatinib L01EA02 Dasatinib L01EA03 Nilotinib L01EA04 Bosutinib L01EA05 Ponatinib L01EA06 Asciminib

L01EB Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors

L01EB01 Gefitinib L01EB02 Erlotinib L01EB03 Afatinib L01EB04 Osimertinib L01EB05 Rociletinib L01EB06 Olmutinib L01EB07 Dacomitinib L01EB08 Icotinib L01EB09 Lazertinib L01EB10 Mobocertinib L01EB11 Aumolertinib

L01EC B-Raf serine-threonine kinase (BRAF) inhibitors

L01EC01 Vemurafenib L01EC02 Dabrafenib L01EC03 Encorafenib

L01ED Anaplastic lymphoma kinase (ALK) inhibitors

L01ED01 Crizotinib L01ED02 Ceritinib L01ED03 Alectinib L01ED04 Brigatinib L01ED05 Lorlatinib

L01EE Mitogen-activated protein kinase (MEK) inhibitors

L01EE01 Trametinib L01EE02 Cobimetinib L01EE03 Binimetinib L01EE04 Selumetinib L01EE05 Mirdametinib

L01EF Cyclin-dependent kinase (CDK) inhibitors

L01EF01 Palbociclib L01EF02 Ribociclib L01EF03 Abemaciclib

L01EG Mammalian target of rapamycin (mTOR) kinase inhibitors

L01EG01 Temsirolimus L01EG02 Everolimus L01EG03 Ridaforolimus L01EG04 Sirolimus

L01EH Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors

L01EH01 Lapatinib L01EH02 Neratinib L01EH03 Tucatinib

L01EJ Janus-associated kinase (JAK) inhibitors

L01EJ01 Ruxolitinib L01EJ02 Fedratinib L01EJ03 Pacritinib L01EJ04 Momelotinib

L01EK Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors

L01EK01 Axitinib L01EK02 Cediranib L01EK03 Tivozanib L01EK04 Fruquintinib

L01EL Bruton's tyrosine kinase (BTK) inhibitors

L01EL01 Ibrutinib L01EL02 Acalabrutinib L01EL03 Zanubrutinib L01EL04 Orelabrutinib L01EL05 Pirtobrutinib L01EL06 Tirabrutinib

L01EM Phosphatidylinositol-3-kinase (Pi3K) inhibitors

L01EM01 Idelalisib L01EM02 Copanlisib L01EM03 Alpelisib L01EM04 Duvelisib L01EM05 Parsaclisib

L01EN Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors

L01EN01 Erdafitinib L01EN02 Pemigatinib L01EN03 Infigratinib L01EN04 Futibatinib

L01EX Other protein kinase inhibitors

L01EX01 Sunitinib L01EX02 Sorafenib L01EX03 Pazopanib L01EX04 Vandetanib L01EX05 Regorafenib L01EX06 Masitinib L01EX07 Cabozantinib L01EX08 Lenvatinib L01EX09 Nintedanib L01EX10 Midostaurin L01EX11 Quizartinib L01EX12 Larotrectinib L01EX13 Gilteritinib L01EX14 Entrectinib L01EX15 Pexidartinib L01EX17 Capmatinib L01EX18 Avapritinib L01EX19 Ripretinib L01EX21 Tepotinib L01EX22 Selpercatinib L01EX23 Pralsetinib L01EX24 Surufatinib L01EX25 Umbralisib L01EX26 Sitravatinib L01EX27 Capivasertib L01EX28 Repotrectinib QL01EX90 Toceranib

L01F Monoclonal antibodies and antibody drug conjugates

L01FA CD20 (clusters of differentiation 20) inhibitors

L01FA01 Rituximab L01FA02 Ofatumumab L01FA03 Obinutuzumab

L01FB CD22 (clusters of differentiation 22) inhibitors

L01FB01 Inotuzumab ozogamicin L01FB02 Moxetumomab pasudotox

L01FC CD38 (clusters of differentiation 38) inhibitors

L01FC01 Daratumumab L01FC02 Isatuximab

L01FD HER2 (human epidermal growth factor receptor 2) inhibitors

L01FD01 Trastuzumab L01FD02 Pertuzumab L01FD03 Trastuzumab emtansine L01FD04 Trastuzumab deruxtecan L01FD05 Trastuzumab duocarmazine L01FD06 Margetuximab L01FD07 Zanidatamab

L01FE EGFR (epidermal growth factor receptor) inhibitors

L01FE01 Cetuximab L01FE02 Panitumumab L01FE03 Necitumumab

L01FF PD-1/PDL-1 (programmed cell death protein 1/ death ligand 1) inhibitors

L01FF01 Nivolumab L01FF02 Pembrolizumab L01FF03 Durvalumab L01FF04 Avelumab L01FF05 Atezolizumab L01FF06 Cemiplimab L01FF07 Dostarlimab L01FF08 Prolgolimab L01FF09 Tislelizumab L01FF10 Retifanlimab L01FF11 Sugemalimab L01FF12 Serplulimab L01FF13 Toripalimab

L01FG VEGF/VEGFR (vascular endothelial growth factor) inhibitors

L01FG01 Bevacizumab L01FG02 Ramucirumab

L01FX Other monoclonal antibodies and antibody drug conjugates

L01FX01 Edrecolomab L01FX02 Gemtuzumab ozogamicin L01FX03 Catumaxomab L01FX04 Ipilimumab L01FX05 Brentuximab vedotin L01FX06 Dinutuximab beta L01FX07 Blinatumomab L01FX08 Elotuzumab L01FX09 Mogamulizumab L01FX10 Olaratumab L01FX11 Bermekimab L01FX12 Tafasitamab L01FX13 Enfortumab vedotin L01FX14 Polatuzumab vedotin L01FX15 Belantamab mafodotin L01FX16 Oportuzumab monatox L01FX17 Sacituzumab govitecan L01FX18 Amivantamab L01FX19 Sabatolimab L01FX20 Tremelimumab L01FX21 Naxitamab L01FX22 Loncastuximab tesirine L01FX23 Tisotumab vedotin L01FX24 Teclistamab L01FX25 Mosunetuzumab L01FX26 Mirvetuximab soravtansine L01FX27 Epcoritamab L01FX28 Glofitamab L01FX29 Talquetamab L01FX31 Zolbetuximab L01FX32 Elranatamab L01FX33 Tarlatamab L01FX34 Odronextamab L01FX35 Datopotamab deruxtecan L01FX36 Patritumab deruxtecan

L01FY Combinations of monoclonal antibodies and antibody drug conjugates

L01FY01 Pertuzumab and trastuzumab L01FY02 Nivolumab and relatlimab L01FY03 Prolgolimab and nurulimab

L01X Other antineoplastic agents

L01XA Platinum compounds

L01XA01 Cisplatin L01XA02 Carboplatin L01XA03 Oxaliplatin L01XA04 Satraplatin L01XA05 Polyplatillen

L01XB Methylhydrazines

L01XB01 Procarbazine

L01XD Sensitizers used in photodynamic/radiation therapy

L01XD01 Porfimer sodium L01XD03 Methyl aminolevulinate L01XD04 Aminolevulinic acid L01XD05 Temoporfin L01XD06 Efaproxiral L01XD07 Padeliporfin

L01XF Retinoids for cancer treatment

L01XF01 Tretinoin L01XF02 Alitretinoin L01XF03 Bexarotene

L01XG Proteasome inhibitors

L01XG01 Bortezomib L01XG02 Carfilzomib L01XG03 Ixazomib

L01XH Histone deacetylase (HDAC) inhibitors

L01XH01 Vorinostat L01XH02 Romidepsin L01XH03 Panobinostat L01XH04 Belinostat L01XH05 Entinostat L01XH06 Tucidinostat L01XH07 Resminostat

L01XJ Hedgehog pathway inhibitors

L01XJ01 Vismodegib L01XJ02 Sonidegib L01XJ03 Glasdegib

L01XK Poly (ADP-ribose) polymerase (PARP) inhibitors

L01XK01 Olaparib L01XK02 Niraparib L01XK03 Rucaparib L01XK04 Talazoparib L01XK05 Veliparib L01XK06 Pamiparib L01XK52 Niraparib and abiraterone

L01XL Antineoplastic cell and gene therapy

L01XL01 Sitimagene ceradenovec L01XL02 Talimogene laherparepvec L01XL03 Axicabtagene ciloleucel L01XL04 Tisagenlecleucel L01XL05 Ciltacabtagene autoleucel L01XL06 Brexucabtagene autoleucel L01XL07 Idecabtagene vicleucel L01XL08 Lisocabtagene maraleucel L01XL09 Tabelecleucel L01XL10 Nadofaragene firadenovec L01XL11 Lifileucel L01XL12 Obecabtagene autoleucel

L01XM Isocitrate dehydrogenase (IDH) inhibitors

L01XM01 Enasidenib L01XM02 Ivosidenib L01XM03 Olutasidenib L01XM04 Vorasidenib

L01XU Other antineoplastic agents (cont.)

Empty group

L01XX Other antineoplastic agents

L01XX01 Amsacrine L01XX02 Asparaginase L01XX03 Altretamine L01XX05 Hydroxycarbamide L01XX07 Lonidamine L01XX08 Pentostatin L01XX10 Masoprocol L01XX11 Estramustine L01XX16 Mitoguazone L01XX18 Tiazofurine L01XX23 Mitotane L01XX24 Pegaspargase L01XX27 Arsenic trioxide L01XX29 Denileukin diftitox L01XX33 Celecoxib L01XX35 Anagrelide L01XX36 Oblimersen L01XX40 Omacetaxine mepesuccinate L01XX41 Eribulin L01XX44 Aflibercept L01XX46 Olaparib L01XX52 Venetoclax L01XX53 Vosaroxin L01XX57 Plitidepsin L01XX58 Epacadostat L01XX66 Selinexor L01XX67 Tagraxofusp L01XX69 Lurbinectedin L01XX72 Tazemetostat L01XX73 Sotorasib L01XX74 Belzutifan L01XX75 Tebentafusp L01XX77 Adagrasib L01XX78 Navitoclax L01XX79 Eflornithine L01XX80 Imetelstat L01XX81 Nirogacestat L01XX82 Darinaparsin L01XX83 Para-toluenesulfonamide L01XX84 Pelabresib L01XX85 Idroxioleic acid L01XX86 Calaspargase pegol QL01XX91 Tigilanol tiglate QL01XX92 Verdinexor

L01XY Combinations of antineoplastic agents

L01XY01 Cytarabine and daunorubicin L01XY04 Bifikafusp alfa and onfekafusp alfa

References

  1. "ATC (Anatomical Therapeutic Chemical Classification System) – Synopsis". National Institutes of Health. Retrieved 1 February 2020. https://www.nlm.nih.gov/research/umls/sourcereleasedocs/current/ATC/index.html ↩

  2. World Health Organization. "Anatomical Therapeutic Chemical (ATC) Classification". World Health Organization. Retrieved 3 January 2022. /wiki/World_Health_Organization ↩

  3. "Structure and principles". WHO Collaborating Centre for Drug Statistics Methodology. 15 February 2018. Retrieved 3 January 2022. https://www.whocc.no/atc/structure_and_principles/ ↩

  4. "ATC/DDD Index 2022: code L01". WHO Collaborating Centre for Drug Statistics Methodology. http://www.whocc.no/atc_ddd_index/?code=L01 ↩

  5. "ATCvet Index 2022: code QL01". WHO Collaborating Centre for Drug Statistics Methodology. http://www.whocc.no/atcvet/atcvet_index/?code=L01 ↩